Genesis Medtech Collaborates with Penumbra to Expand Neurovascular Market in China
- Partnership to be in tandem with formation of Genesis Medtech s Neurovascular Franchise, pending an ongoing full acquisition of Hua Medtech
- The collaboration will position Genesis MedTech ( Genesis ) as the largest local company in China s neurovascular space
News provided by
Share this article
Share this article
SINGAPORE, Jan. 19, 2021 /PRNewswire/ Genesis MedTech Group has reached a consensus to fully acquire Hua Medtech as part of its plans to set up a specialised neurovascular franchise, which has entered into a strategic cooperation with Penumbra, Inc., an NYSE listed, global healthcare company focused on innovative therapies, for the domestic sales and production of products with Penumbra s technology for the Chinese market.